Abstract
The prognosis of systemic lupus erythematosus (SLE) is considerably worse when accompanied by renal involvement. In order to study the outcome within a year of histologic diagnosis of severe lupus nephritis, we obtained data on 25 patients from nine participating centers. All these patients fulfilled clearly defined histologic criteria of severe lupus nephritis, thus enabling us to evaluate a homogeneous group of patients. During a mean follow-up period of 9.4 months, there appeared to be an equal probability that the renal function would improve, remain stable, or worsen as assessed by changes in serum creatinine concentration. One patient died and another patient reached end-stage renal disease (ESRD), a combined crude mortality plus ESRD rate of 8% for 9.4 months. As both these patients had serum creatinine values of less than 2 mg/dL at the time of diagnosis of severe lupus nephritis, it appears that normal or mildly impaired renal function at the time of diagnosis does not ensure benign outcome. These features should be considered when new studies on SLE nephritis are planned or any new therapeutic modality is evaluated.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 239-243 |
| Number of pages | 5 |
| Journal | American Journal of Kidney Diseases |
| Volume | 8 |
| Issue number | 4 |
| DOIs | |
| State | Published - 1986 |
Funding
From the Lupus Nephritis Collaborative Study Group: Clinical Coordinating Center: Edmund J. Lewis, MD (Principal Investigator), B. S. Kasinath, MD (Co-principal Investigator), Rush-Presbyterian-St. Luke's Medical Center, Chicago, Ill. Biostatistics Coordinating Center: John Lachin, SeD, George Washington University, Bethesda, Md. Central Immunology Laboratory: Ani! K. Bidani, MD (Director), RushPresbyterian-St. Luke's Medical Center, Chicago, Ill. Central Pathology Laboratory: Melvin M. Schwartz, MD (Director), Rush-Presbyterian-St. Luke's Medical Center, Chicago, Ill. Clinics: Marc A. Pohi, MD, John Clough, MD, Gordon Gephardt, MD, Cleveland Clinic, Cleveland, Ohio; Tomas Berl, MD, University of Colorado, Denver, Colo; Nathan Levin, MD, Henry Ford Hospital, Detroit, Mich; Lawrence G. Hunsicker, MD, University of Iowa, Iowa City, Iowa; Norman Simon, MD, Hartmann Friederici, MD, Evanston Hospital, Evanston, Ill; Frank del Greco, MD, Frank A. Carone, MD, Northwestern Univesity, Chicago, Ill; Lee Hebert, MD, Hari M. Sharma, MD, Ohio State University, Columbus, Ohio; Eric Neilson, MD, John Tomazewski, MD, University of Pennsylvania, Philadelphia, Pa; Howard L. Corwin, MD, Melvin M. Schwartz, MD, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Ill; Andrew Levey, MD, Angelo Ucci, MD, Tufts-New England Medical Center, Boston, Mass; Howard Shapiro, MD, Barbara F. Rosenberg, MD, William Beaumont Hospital, Royal Oak, Mich; Jacob Lemann, MD, John Carancis, MD, University of Wisconsin Medical College, Milwaukee, Wis; Kenneth Shapiro, MD, Praveen Chander, MD, New York Medical College, I1llhalla, NY; Fred Wittaker, MD, John W. Graves, MD, Maureen Mayes, MD, Roger Riley, MD, West Virginia University, Morgantown, wv. Supported by NIH Grant R01-AM27770.
Keywords
- Systemic lupus erythematosus
- severe glomerulonephritis
ASJC Scopus subject areas
- Nephrology